Delhi, India

Milind Moreshwar Gharpure


Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 42(Granted Patents)


Location History:

  • Patparganj, IN (1997)
  • Delhi, IN (1997 - 1999)

Company Filing History:


Years Active: 1997-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Milind Moreshwar Gharpure: Innovator in Taxol Derivatives

Introduction

Milind Moreshwar Gharpure is a notable inventor based in Delhi, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of taxol derivatives. With a total of 3 patents to his name, Gharpure's work is recognized for its innovative approach to drug formulation.

Latest Patents

Gharpure's latest patents include the invention of 2-debenzoyl-2-acyl taxol derivatives and methods for making the same. This invention relates to compounds that have the general formula where R1 is an alkyl or substituted alkyl, and R2 is selected from the group consisting of H and C(O)Ra. The compounds also include various other groups, providing a versatile framework for pharmaceutical applications. These derivatives are crucial for enhancing the efficacy of taxol, a well-known anticancer drug.

Career Highlights

Milind Moreshwar Gharpure is associated with Virginia Tech Intellectual Properties, Inc., where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding and application of taxol derivatives in medical treatments.

Collaborations

Gharpure has collaborated with esteemed colleagues such as David G Kingston and Ashok Gopal Chaudhary. These partnerships have fostered a collaborative environment that enhances research and development efforts in the pharmaceutical sector.

Conclusion

Milind Moreshwar Gharpure's contributions to the field of pharmaceuticals, particularly through his innovative patents, highlight his role as a key inventor in the development of taxol derivatives. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…